埃沃洛库马布在患有或没有多血管冠状动脉疾病的患者的长期疗效
Daniel J McClintick1, Michelle L O'Donoghue2, Gaetano M De Ferrari3
1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Journal of the American College of Cardiology
|February 7, 2024
概括
在患有多血管疾病 (MVD) 和没有多血管疾病的患者中,Evolocumab显著降低了主要心血管事件. 这种药物是药物,是药物.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 福里尔试验证明了埃沃洛库马布在减少心血管事件方面的有效性.
- 患有多血管疾病 (MVD) 的患者在使用evolocumab时显示出更大的风险降低.
- 在FOURIER开放标签扩展 (FOURIER-OLE) 扩展了长期益处评估的后续工作.
研究的目的:
- 评估埃沃洛库马布在患有或没有MVD的患者中对心血管的长期益处.
- 根据MVD的存在,在患者子组中比较evolocumab的疗效.
主要方法:
- 福里尔随机选择了27564名患者;6635人进入了福里尔-OLE.
- 根据MVD的存在 (≥2个大血管的狭窄) 将患者分类.
- 主要终点:结合心血管死亡,心肌梗塞,中风,不稳定的心痛住院治疗或再血管.
主要成果:
- 埃沃洛库马布在患有MVD的患者中 (23%的主要,31%主要次要) 与没有MVD的患者相比 (11%的主要,15%主要次要) 显示出更大的风险降低.
- 益处的幅度随着时间的推移而增加,MVD患者的风险降低达到37-38%,非MVD患者的风险降低达到23-28%.
- 对关键次要终点 (P=0.031) 观察到显著的相互作用,表明基于MVD状态的差异效益.
结论:
- 埃沃洛库马布在MVD和非MVD患者中有效地减少了主要的不良心血管事件.
- 在患有MVD的患者中,evolocumab对心血管的益处更为明显,并且更早发生.
- 这些发现支持早期和密集的低密度脂蛋白胆固醇降低evolocumab在患有和没有MVD的患者.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
182
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
182
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
515
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
515